In a significant push to bridge the gap between clinical innovation and patient outcomes, the esteemed journal Expert Review of Gastroenterology & Hepatology has officially issued a call for submissions for a specialized Article Collection dedicated to "Biliary Cancer Prevention and Treatment." As the global oncological community grapples with the aggressive nature of cholangiocarcinoma and gallbladder cancer, this initiative seeks to aggregate high-impact research, translational findings, and clinical strategies to reshape the landscape of hepatobiliary care.
The call for papers, managed by the publishing house Taylor & Francis, represents a strategic effort to consolidate the latest evidence-based practices for a disease often characterized by late-stage diagnosis and limited therapeutic windows.
Main Facts: A Specialized Focus on Aggressive Malignancies
The initiative aims to curate a comprehensive repository of knowledge that addresses the full spectrum of biliary tract cancers. These malignancies, which include intrahepatic, perihilar, and distal cholangiocarcinoma, as well as gallbladder cancer, have historically presented immense challenges due to their anatomical complexity and high rates of recurrence.
Scope of the Collection
The journal is soliciting a diverse range of contributions, including:
- Original Research: Data-driven studies that introduce novel therapeutic targets or diagnostic methods.
- Reviews: Systematic syntheses of current literature that evaluate the efficacy of existing treatment protocols.
- Drug Profiles: Detailed analyses of emerging systemic therapies, including targeted inhibitors and immunotherapy.
- Editorials: Concise, high-level perspectives on the future trajectory of the field.
By inviting contributions from a multidisciplinary cohort—including oncologists, hepatobiliary surgeons, pathologists, and translational scientists—Taylor & Francis aims to foster a holistic dialogue that transcends traditional departmental silos.
Chronology: The Evolution of Hepatobiliary Research
To understand the necessity of this new Article Collection, one must look at the timeline of progress in biliary oncology over the past decade.
2014–2018: The Era of Standardized Chemotherapy
For years, the treatment of biliary tract cancers was largely tethered to the GEMOX (gemcitabine and oxaliplatin) regimen, established by the landmark ABC-02 trial. During this period, progress was incremental, focusing on refining surgical margins and palliative care strategies.
2019–2022: The Molecular Revolution
The landscape began to shift dramatically with the advent of next-generation sequencing. The identification of actionable mutations—most notably FGFR2 fusions and IDH1 mutations—marked a turning point. Regulatory bodies began approving targeted therapies for patients with specific molecular profiles, moving the field away from a "one-size-fits-all" chemotherapy approach.
2023–Present: The Shift to Precision Medicine
Today, the focus has expanded to include the tumor microenvironment and the role of immunotherapy in combination with traditional regimens. The announcement of this Expert Review of Gastroenterology & Hepatology collection serves as a direct response to this rapid evolution. It aims to capture the "next wave" of data, specifically addressing the integration of these advanced therapies into standard clinical workflows.
Supporting Data: Addressing the Clinical Challenge
The urgency of this call for papers is underscored by epidemiological data. Biliary tract cancers, while relatively rare compared to other gastrointestinal malignancies, exhibit a high degree of mortality.
Global Burden and Diagnostic Hurdles
- Incidence: While rare in Western populations, the incidence of cholangiocarcinoma is rising globally, partly attributed to increased awareness and improved diagnostic imaging.
- Prognosis: The five-year survival rate remains suboptimal, largely because the majority of patients present with unresectable, locally advanced, or metastatic disease.
- Molecular Heterogeneity: Recent data suggests that biliary cancers are not a monolithic disease. Studies indicate that genomic profiling can identify unique therapeutic targets in up to 40% of patients, yet the integration of this testing into routine practice remains inconsistent globally.
This collection intends to address these gaps by highlighting papers that detail successful molecular profiling programs and the implementation of innovative surgical techniques, such as portal vein embolization and extended liver resections, which have shown promise in improving R0 resection rates.
Official Perspectives: Bridging the Expert-Patient Divide
The initiative is overseen by the editorial team at Taylor & Francis, with Commissioning Editor Olivia Clovis-Corbett acting as the primary point of contact for potential contributors. The journal’s editorial board emphasizes that this collection is not merely an academic exercise but a practical resource for clinicians on the front lines.
The Editorial Vision
The editorial board of Expert Review of Gastroenterology & Hepatology has indicated that the collection will prioritize works that offer "clinical utility." This means that theoretical research is secondary to research that can be translated into bedside care.
"Our goal is to provide a comprehensive roadmap for the next generation of hepatobiliary care," notes the editorial brief. "By bringing together the world’s leading surgeons and medical oncologists, we hope to establish a consensus on best practices that can be applied in both tertiary referral centers and community hospitals."
The journal encourages researchers who have conducted clinical trials or observational studies on novel treatment protocols—including neoadjuvant approaches—to submit their findings. Furthermore, there is a specific interest in the role of liquid biopsies and circulating tumor DNA (ctDNA) in the early detection and monitoring of treatment response, areas that are currently experiencing an explosion of research interest.
Implications: The Future of Biliary Cancer Care
The implications of this Article Collection are far-reaching. By aggregating high-quality, peer-reviewed data, Taylor & Francis is facilitating a faster dissemination of knowledge. In a field where clinical trials are often international and multicentric, the ability to synthesize findings into a single repository is invaluable.
Impact on Clinical Practice
- Standardization of Care: The collection will likely serve as a foundational text for clinicians seeking to adopt the latest global standards in surgical resection and systemic therapy.
- Accelerating Drug Approval: By highlighting successful outcomes from early-phase trials, the collection provides a platform for promising therapies to gain the visibility needed to transition into Phase III trials.
- Educational Outreach: For junior clinicians and fellows, the collection serves as a comprehensive educational resource, summarizing the current state of the art in a rapidly changing field.
A Call to Action for the Global Community
The window for submission is currently open, and the journal is actively seeking diverse international perspectives. As healthcare systems globally face the challenge of rising cancer rates, the sharing of data across borders is essential. Whether it is a novel surgical technique developed in East Asia or a new molecular inhibitor tested in a European clinical trial, the collection aims to provide a platform for these developments to be reviewed and implemented.
For authors interested in contributing to this pivotal collection, the process involves a direct engagement with the commissioning team. By providing a streamlined path for submission, Taylor & Francis hopes to lower the barrier for researchers to share their findings with the broader medical community.
In conclusion, the "Biliary Cancer Prevention and Treatment" collection represents a significant milestone in the ongoing fight against hepatobiliary malignancies. As the medical community continues to unlock the molecular secrets of these aggressive cancers, initiatives like this ensure that the latest scientific discoveries do not remain locked in journals but reach the clinics where they can change—and extend—patient lives.
For those interested in contributing to this collection, or for further information regarding submission guidelines, please contact Olivia Clovis-Corbett, Commissioning Editor, to discuss your research proposal.
About the Author
